A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

NCT01707147 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3219

Last updated 2019-01-11

Study results available
· View outcomes & findings →

Summary

The aim of this study is to monitor safety and efficacy of treatment with linagliptin in Korean patients with type 2 diabetes mellitus in routine clinical settings.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Trajenta tablet

Linagliptin

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-16
Primary Completion
2017-07-11
Completion
2017-07-11

Countries

  • South Korea

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01707147 on ClinicalTrials.gov